Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid malignancies. Brentuximab vedotin is approved for use in Hodgkin’s lymphoma and Trastuzumab emtansine is approved for breast cancer. Here, we discuss the preclinical experience as well as clinical trials, with a specific emphasis on the clinical outcomes and side effects, in addition to linker strategies for five different ADCs, in order to describe different approaches in the development of this new class of anticancer agents.
While the antibody and drug are of vital importance in the direct elimination of cancer cells, more advanced linker technology was instrumental in the delivery of more potent drugs with fewer side effects. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. Received: MaAccepted: MaPublished: MaAbstract Keywords: antibody drug conjugates, oncotargets, immunotoxins Verma 1ġ Department of Medicine, Albert Einstein College of Medicine, Bronx, NY Barta 1,*, Carolina Schinke 1, Ira Braunschweig 1, Yiyu Zhou 1, Amit K.
0 kommentar(er)
